Management of Dysautonomia and Spinal Cord Syndrome with Negative Workup
This patient requires urgent neurology consultation, lumbar puncture with comprehensive CSF analysis including paraneoplastic and autoimmune encephalopathy panels, and empiric high-dose corticosteroids while awaiting results, as this presentation suggests seronegative autoimmune myelitis or paraneoplastic syndrome despite negative initial antibody testing.
Immediate Diagnostic Workup
The negative MRI does not exclude inflammatory myelopathy—10% of MOG-antibody-associated myelitis presents with initially negative spinal cord MRI despite severe disability 1. Your diagnostic approach must include:
Essential CSF Analysis
- Cell count with differential, protein, glucose
- Cytology to exclude malignant cells
- Oligoclonal bands (already negative, but document)
- Paraneoplastic antibody panel: anti-Hu (ANNA-1), anti-ganglionic acetylcholine receptor, N-type voltage-gated calcium channel antibodies 2
- Autoimmune encephalopathy panel including NMDAR, LGI1, CASPR2 3
- Viral PCRs (HSV, VZV, enterovirus) to exclude infectious myelitis 4
Additional Serum Testing
- Repeat MOG-IgG testing if initial test was not performed with live-cell assay (most sensitive method) 5
- Ganglionic acetylcholine receptor antibodies (for dysautonomia) 2
- Comprehensive paraneoplastic panel
- Screen for systemic autoimmune disease: ANA, anti-Ro/La, anti-dsDNA, ANCA 4
- Exclude metabolic causes: B12, folate, TSH, HIV, RPR, copper 4
Repeat Imaging
Order repeat MRI spine with thin axial cuts through symptomatic levels and gadolinium contrast 4. In MOG-associated disease, lesions may become apparent on follow-up imaging even when initially negative 1. Look specifically for:
- Central gray matter involvement (H-sign on axial T2) 6
- Longitudinally extensive lesions (≥3 vertebral segments)
- Nerve root enhancement suggesting inflammatory radiculopathy 4
Acute Management Strategy
Corticosteroid Therapy
Initiate IV methylprednisolone 1-2 g daily for 3-5 days immediately 4. The combination of spinal cord syndrome with dysautonomia represents severe (Grade 3-4) neurologic toxicity requiring aggressive immunosuppression. Do not delay treatment waiting for antibody results—seronegative autoimmune myelitis exists and responds to immunotherapy 3.
Consider IVIG
Strongly consider adding IVIG 0.4 g/kg/day for 5 days (total 2 g/kg) concurrently with corticosteroids 4. Combined first-line therapy is appropriate when the clinical picture is severe, particularly with dysautonomia suggesting autonomic nervous system involvement 3.
Plasmapheresis as Rescue
If no meaningful response after 2-4 weeks of first-line therapy, add plasmapheresis (5-10 sessions every other day) 3. This is particularly effective in antibody-mediated disease and cases refractory to corticosteroids alone.
Critical Pitfalls to Avoid
Do not assume negative antibodies exclude autoimmune disease: Seronegative NMOSD, MOGAD, and paraneoplastic syndromes exist 7, 8. Clinical presentation and CSF findings guide treatment, not antibody status alone.
Do not dismiss negative MRI: MRI-negative myelitis occurs in 10% of MOG-associated cases with severe disability (median EDSS 7) 1. Symptoms and signs (paraparesis, sensory level, neurogenic bladder, Lhermitte's phenomenon) take precedence.
Monitor for volume shifts in dysautonomic patients: If plasmapheresis is used, dysautonomia increases risk of hemodynamic instability 3.
Evaluate for occult malignancy: Paraneoplastic myelitis with dysautonomia can present with negative initial antibody panels. Consider CT chest/abdomen/pelvis if paraneoplastic antibodies are positive or clinical suspicion is high 2.
Second-Line Immunotherapy
If inadequate response to pulse steroids and IVIG after 2-4 weeks:
- Rituximab 375 mg/m² weekly × 4 doses for suspected antibody-mediated disease (preferred if any antibodies detected or high clinical suspicion) 3, 4
- Cyclophosphamide for suspected cell-mediated disease (paraneoplastic syndromes with intracellular antigens) 3
Maintenance Therapy
After acute treatment response, initiate bridging therapy with oral prednisone taper over 4-6 weeks 2. Consider monthly IVIG or IV methylprednisolone to prevent relapse during steroid taper 3.
Symptomatic Management
- Dysautonomia: Orthostatic vital signs monitoring, midodrine for orthostatic hypotension, fludrocortisone if needed 2
- Neuropathic pain: Gabapentin, pregabalin, or duloxetine (avoid opioids) 2, 4
- Neurogenic bladder/bowel: Intermittent catheterization if retention, bowel regimen for constipation 4
- Frequent neurochecks and pulmonary function monitoring for ascending weakness 2
When to Suspect Specific Etiologies
The combination of myelitis with dysautonomia narrows the differential:
- Paraneoplastic: Anti-Hu, anti-CRMP5, ganglionic AChR antibodies
- Autoimmune encephalomyelitis: May have normal initial MRI, CSF pleocytosis typical 3
- Seronegative NMOSD/MOGAD: Repeat antibody testing with live-cell assay, follow-up MRI may reveal lesions 1, 5
- Immune checkpoint inhibitor-related (if applicable): Requires permanent discontinuation 2, 4
The key principle: treat empirically based on clinical syndrome severity while completing diagnostic workup—do not withhold immunotherapy awaiting antibody confirmation in severe presentations 3.